临床儿科杂志 >

2025 , Vol. 43 >Issue 7: 543 - 548

DOI: https://doi.org/10.12372/jcp.2025.24e1371

临床报道

SMN1基因复合杂合变异脊髓性肌萎缩症患者疾病修正治疗的临床疗效分析

  • 段浩林 ,
  • 张慈柳 ,
  • 熊娟 ,
  • 庞楠 ,
  • 尹飞 ,
  • 彭镜
展开
  • 1.中南大学湘雅医院儿童医学中心(湖南长沙 410008)
    2.湖南省智力障碍研究中心(湖南长沙 410008)

收稿日期: 2024-12-23

  录用日期: 2025-05-19

  网络出版日期: 2025-06-27

基金资助

湖南省重点研发计划项目(2022SK2036)

收起

Clinical efficacy analysis of disease-modifying therapies for spinal muscular atrophy with SMN1 gene compound heterozygous variants

  • DUAN Haolin ,
  • ZHANG Ciliu ,
  • XIONG Juan ,
  • PANG Nan ,
  • YIN Fei ,
  • PENG Jing
Expand
  • 1. Children's Medical Center, Xiangya Hospital Central South University, Changsha 410008, Hunan, China
    2. Hunan Provincial Research Center for Intellectual Disabilities, Changsha 410008, Hunan, China

Received date: 2024-12-23

  Accepted date: 2025-05-19

  Online published: 2025-06-27

Fold

摘要

目的 探讨SMN1基因复合杂合变异所致脊髓性肌萎缩症（SMA）接受疾病修正治疗的临床疗效。方法 回顾性收集2例复合杂合变异SMA患儿的临床资料、治疗经过以及随访结果，并结合国内外相关的病例报道进行分析。结果 2例患儿均为SMAⅠ型，SMN1基因存在外显子7杂合缺失和1处微小变异（分别为c.188C>A和c.683T>A）。其中例1为4岁4个月男性患儿，7月龄起病时开始康复训练，1岁6个月接受诺西那生钠治疗，3岁加用利司扑兰联合治疗，3岁10个月停康复。治疗后患儿运动功能缓慢进步，获得翻身至侧位和扶坐能力，目前可扶坐。例2为1岁8个月女性患儿，4月龄起病时开始康复训练，7月龄口服利司扑兰，因皮肤颜色持续变黑，于1岁5个月改为诺西那生钠治疗。药物治疗结合康复训练后患儿运动功能显著进步，获得独坐和扶站运动里程碑，目前可独站7~8秒、跨步。结论 疾病修正治疗能改善复合杂合变异SMA患儿的总体预后，并提高患儿的运动功能。

关键词： 脊髓性肌萎缩症; 复合杂合变异; 疾病修正治疗; 临床疗效; 儿童

本文引用格式

段浩林 , 张慈柳 , 熊娟 , 庞楠 , 尹飞 , 彭镜 . SMN1基因复合杂合变异脊髓性肌萎缩症患者疾病修正治疗的临床疗效分析[J]. 临床儿科杂志, 2025 , 43(7) : 543 -548 . DOI: 10.12372/jcp.2025.24e1371

Abstract

Objective To investigate the clinical efficacy of disease-modifying therapies (DMTs) in spinal muscular atrophy (SMA) patients with SMN1 gene compound heterozygous variants. Methods A retrospective analysis was performed on two cases with SMN1 compound heterozygous SMA, including clinical data, treatment approaches, and prognosis. Clinical findings were contextualized through a systematic literature review of analogous cases. Results Two SMA type I patients exhibited SMN1 compound heterozygous: a 4-year-old male (Patient 1) with exon 7 heterozygous deletion and c.188C>A variation, and a 1.7-year-old female (Patient 2) with exon 7 heterozygous deletion and c.683T>A variation. Patient 1 initiated rehabilitation at 7 months of age, received nusinersen treatment at 1 year and 6 months, added risdiplam as combination therapy at 3 years, and discontinued rehabilitation at 3 years and 10 months. Following DMTs, the patient showed slow progress in motor function, acquiring the ability to roll over to the side and sit with support, and is currently able to sit with assistance. Patient 2 started rehabilitation at 4 months of age, received risdiplam at 7 months, and switched to nusinersen treatment at 1 year and 5 months due to persistent darkening of skin color. The combination of DMTs and rehabilitation resulted in significant improvement in the patient's motor function, achieving milestones such as sitting independently and standing with support. Currently, she can stand independently for 7-8 seconds and take steps. Conclusion DMTs can improve the overall prognosis of children with compound heterozygous SMA and enhance their motor function.

Key words： spinal muscular atrophy; compound heterozygous mutation; disease-modifying therapy; clinical efficacy; child

参考文献

[1] Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy- a literature review[J]. Orphanet J Rare Dis, 2017, 12(1): 124.
[2] Peeters K, Chamova T, Jordanova A. Clinical and genetic diversity of smn1-negative proximal spinal muscular atrophies[J]. Brain, 2014, 137(Pt 11):2879-2896.
[3] Cartegni L, Hastings ML, Calarco JA, et al. Determinants of exon 7 splicing in the spinal muscular atrophy genes, smn1 and smn2[J]. Am J Hum Genet, 2006, 78(1): 63-77.
[4] Chi YW, Qiao Y, Ma Y. Spinal muscular atrophy caused by compound heterozygous smn1 mutations: two cases and literature review[J]. Neurol Sci, 2024: 8.
[5] Wijaya YOS, Ar Rchmah M, Niba ETE, et al. Phenotypes of SMA patients retaining SMN1 with intragenic mutation[J]. Brain Dev, 2021, 43(7): 745-758.
[6] Vezain M, Gérard B, Drunat S, et al. A leaky splicing mutation affecting SMN1 exon 7 inclusion explains an unexpected mild case of spinal muscular atrophy[J]. Hum Mutat, 2011, 32(9): 989-994.
[7] 都娟, 瞿宇晋, 熊晖, 等. 脊髓性肌萎缩症三例及其家系的基因突变分析[J]. 中华儿科杂志, 2011, 49(6): 411-415.
  Du J, Qu YJ, Xiong X, et al. Mutation analysis of SMN1 gene in patients with spinal muscular atrophy[J]. Zhonghua Erke Zazhi, 2011, 49(6): 411-415.
[8] Qu YJ, Song F, Yang YL, et al. Compound heterozygous mutation in two unrelated cases of Chinese spinal muscular atrophy patients[J]. Chin Med J (Engl), 2011, 124(3): 385-389.
[9] Fraidakis MJ, Drunat S, Maisonobe T, et al. Genotype-phenotype relationship in 2 SMA III patients with novel mutations in the Tudor domain[J]. Neurology, 2012, 78(8): 551-556.
[10] Kirwin SM, Vinette KM, Gonzalez IL, et al. A homozygous double mutation in SMN1: a complicated genetic diagnosis of SMA[J]. Mol Genet Genom Med, 2013, 1(2):113-117.
[11] Yamamoto T, Sato H, Lai PS, et al. Intragenic mutations in SMN1 may contribute more significantly to clinical severity than SMN2 copy numbers in some spinal muscular atrophy (SMA) patients[J]. Brain Dev, 2014, 36(10): 914-920.
[12] Qu YJ, Bai JL, Cao YY, et al. A rare variant (c.863G > T) in exon 7 of SMN1 disrupts mRNA splicing and is responsible for spinal muscular atrophy[J]. Eur J Hum Genet, 2016, 24(6): 864-870.
[13] Ronchi D, Previtali SC, Sora MG, et al. Novel splice-site mutation in SMN1 associated with a very severe SMA-I phenotype[J]. J Mol Neurosci, 2015, 56(1): 212-215.
[14] Takarada T, Ar Rochmah M, Harahap NIF, et al. SMA mutations in SMN Tudor and C-terminal domains destabilize the protein[J]. Brain Dev, 2017, 39(7):606-612.
[15] Ar Rochmah M, Awano H, Awaya T, et al. Spinal muscular atrophy carriers with two SMN1 copies[J]. Brain Dev, 2017, 39(10): 851-860.
[16] Wu S, Li YL, Cheng NY, et al. c.835-5T>G Variant in SMN1 gene causes transcript exclusion of exon 7 and spinal muscular atrophy[J]. J Mol Neurosci, 2018, 65(2):196-202.
[17] 盛志强, 袁嫣然, 赵兵. SMN1基因复合杂合变异导致脊髓性肌萎缩症一例[J]. 中华医学遗传学杂志, 2019, 3 (11): 115.
  Sheng ZQ, Yuan YR, Zhao B. A case of spinal muscular atrophy caused by compound heterozygous variants in the SMN1 gene[J]. Zhonghua Yichuanxue Zazhi, 2019, 3 (11): 115.
[18] Zhao XC, Wang YH, Mei SY, et al. Identification of two novel SMN1 point mutations associated with a very severe SMA-I phenotype[J]. Eur J Med Genet, 2020, 63(9): 104006.
[19] Eggermann T, Eggermann K, Elbracht M, et al. A new splice site mutation in the SMN1 gene causes discrepant results in SMN1 deletion screening approaches[J]. Neuromuscul Disord, 2008, 18(2):146-149.
[20] Bai J, Qu Y, Song F, et al. Dual mechanism of a new SMN1 variant (c.835G > C, p.Gly279Arg) by interrupting exon 7 skipping and YG Oligomerization in Causation of spinal muscular atrophy[J]. J Mol Neurosci, 2021, 71(1): 112-121.
[21] 姚妹, 冯艺杰, 夏雨, 等. 复合杂合变异脊髓性肌萎缩症1例报告[J]. 临床儿科杂志, 2022, 40(3): 212-217.
  Yao X, Feng YJ, Xia Y, et al. A rare case of children with compound heterozygous variant of spinal muscular atrophy[J]. Linchuang Erke Zazhi, 2022, 40(3): 212-217.
[22] 古艳, 李丽萍, 陈辉, 等. SMN基因复合杂合变异所致脊髓性肌萎缩症1例及患儿的家系分析[J]. 中华医学遗传学杂志, 2023, 40(11): 1387-1391.
  Gu Y, Li LP, Chen H, et al. Analysis of a Chinese pedigree affected with Spinal muscular atrophy due to compound heterozygous variants of SMN gene[J]. Zhonghua Yixue Yichuanxue Zazhi, 2023, 40(11): 1387-1391.
[23] Ma K, Zhang KH, Chen DF, et al. Real-world evidence: Risdiplam in a patient with spinal muscular atrophy type I with a novel splicing mutation and one SMN2 copy[J]. Hum Mol Genet, 2024, 33(13):1120-1130.
[24] Feldk?tter M, Schwarzer V, Wirth R, et al. Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy[J]. Am J Hum Genet, 2002, 70: 358-368.
[25] Niba ETE, Nishio H, Wijaya YOS, et al. Stability and oligomerization of mutated SMN protein determine clinical severity of spinal muscular atrophy[J]. Genes (Basel), 2022, 13(2): 205.
[26] Qu YJ, Ge L, Jin-Li Bai JL, et al. p.Val19Glyfs*21 and p.Leu228* variants in the survival of motor neuron 1 trigger nonsense-mediated mRNA decay causing the SMN1 PTC+ transcripts degradation[J]. Mutat Res, 2017, 806: 31-38.
[27] 罗智强, 路新国, 刘丽琴, 等. 诺西那生钠治疗症状前5q脊髓性肌萎缩症1例疗效分析[J]. 临床儿科杂志, 2022, 40(3): 208-211.
  Luo ZQ, Lu XG, Liu LQ, et al. Clinical efficacy of nusinersen in treating presymptomatic 5 q spinal muscular atrophy: a case report and literature review[J]. Linchuang Erke Zazhi, 2022, 40(3): 208-211.
[28] 罗智强, 陈黎, 路新国, 等. 中国大陆首例症状前治疗脊髓性肌萎缩症患儿43月龄随访报告[J]. 临床儿科杂志, 2025, 43(1): 40-44.
  Luo ZQ, Chen L, Lu XG, et al. The treatment of the first case of presymptomatic spinal muscular atropy in the Chinese Mainland:a case report with 43 months follow-up[J]. Linchuang Erke Zazhi, 2025, 43(1): 40-44.
[29] Baranello G, Gorni K, Daigl M, et al. Prognostic Factors and treatment-effect modifiers in spinal muscular atrophy[J]. Clin Pharmacol Ther, 2021, 110(6): 1435-1454.
[30] 刘芳芳, 王杰, 郭晓华, 等. 利司扑兰单药治疗儿童脊髓性肌萎缩症随访1年的病例系列报告[J]. 中国循证儿科杂志, 2024, 19(2): 93-97.
  Liu FF, Wang J, Guo XH, et al. One year follow-up of Risdiplam monotherapy in children with spinal muscular atrophy: A case series report[J]. Zhongguo Xunzheng Erke Zazhi, 2024, 19(2): 93-97.
Options
文章导航

/

〈 〉

沪ICP备06032584号-5　　 沪公网安备 31011002000392号
网站版权 © 《临床儿科杂志》编辑部
地址：上海市杨浦区控江路1665号(200092)　电话: 021-25076489　E-mail: jcperke@126.com
本系统由北京玛格泰克科技发展有限公司设计开发